Refine
Document Type
- Article (23)
Language
- English (23)
Has Fulltext
- yes (23)
Is part of the Bibliography
- no (23)
Keywords
- cirrhosis (5)
- portal hypertension (5)
- NASH (4)
- ACLF (3)
- Cirrhosis (3)
- NAFLD (3)
- Portal veins (3)
- inflammation (3)
- Liver diseases (2)
- Liver fibrosis (2)
- Portal hypertension (2)
- Veins (2)
- acute decompensation (2)
- liver fibrosis (2)
- steatosis (2)
- 16S rRNA sequencing (1)
- ADGRE1 (1)
- ALD (1)
- Aminotransferases (1)
- Angiogenesis (1)
- Angiography (1)
- Ascites (1)
- Bilirubin (1)
- Biomarkers (1)
- Blood (1)
- Blood plasma (1)
- Collagen (1)
- Collagens (1)
- EMR1 (1)
- Extracellular matrix (1)
- F4/80 (1)
- Fatty liver (1)
- Fibrosis (1)
- HIV (1)
- Hepatic stellate cell (1)
- Mechanisms of disease (1)
- Metalloproteinases (1)
- Molecular medicine (1)
- PDE‐5‐inhibitor (1)
- Patients (1)
- Platelets (1)
- Prostaglandin (1)
- Roux-en-Y gastric bypass (1)
- SPSS (1)
- Steatosis (1)
- TGF-β1 (1)
- TGR(mREN2)27 (1)
- Thrombosis (1)
- Thromboxane (1)
- Western diet (1)
- White blood cells (1)
- acute-on-chronic liver failure (1)
- acute-on-chronic liver failure (ACLF) (1)
- acute‐on‐chronic liver failure (1)
- animal model (1)
- bacterial translocation (1)
- beta‐trace protein (1)
- caspase-1 (1)
- circulation (1)
- computed tomography (1)
- cystatin C (1)
- decompensated liver cirrhosis (1)
- erectile dysfunction (1)
- fibrosis (1)
- hemodynamic (1)
- hepatic encephalopathy (1)
- hepatic stellate cells (1)
- hepatocellular cancer (1)
- immunity (1)
- in vitro models (1)
- inflammasome (1)
- liver (1)
- liver steatosis (1)
- macrophage (1)
- metabolic liver disease (1)
- microbiome (1)
- mini gastric bypass (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mouse (1)
- non‐selective beta‐blocker (1)
- one anastomosis gastric bypass (1)
- organ dysfunction (1)
- organ failure (1)
- pancreatic cancer (1)
- pancreatic surgery (1)
- portosystemic shunt (1)
- postoperative complications (1)
- renal function (1)
- renin-angiotensin system (1)
- signature (1)
- spontaneous portosystemic shunt (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- weight loss (1)
- fibrogenesis (1)
Institute
- Medizin (23)
- Geowissenschaften (1)
Introduction: Recent animal studies have shown that the alternate renin-angiotensin system (RAS) consisting of angiotensin-converting enzyme 2 (ACE2), angiotensin-(1–7) (Ang-(1–7)) and the Mas receptor is upregulated in cirrhosis and contributes to splanchnic vasodilatation and portal hypertension. To determine the potential relevance of these findings to human liver disease, we evaluated its expression and relationship to the patients’ clinical status in subjects with cirrhosis. Methods: Blood sampling from peripheral and central vascular beds was performed intra-operatively for cirrhotic patients at the time of liver transplantation (LT) or trans-jugular intra-hepatic portosystemic shunt (TIPS) procedures to measure angiotensin II (Ang II) and Ang-(1–7) peptide levels and ACE and ACE2 enzyme activity. Relevant clinical and hemodynamic data were recorded pre-operatively for all subjects and peripheral blood sampling was repeated 3 months or later post-operatively. Results: Ang-(1–-7) and ACE2 activity were up-regulated more than twofold in cirrhotic subjects both at the time of LT and TIPS and levels returned to comparable levels as control subjects post-transplantation. Ang-(1–7) levels correlated positively with the degree of liver disease severity, as measured by the model for an end-stage liver disease (MELD) and also with clinical parameters of pathological vasodilatation including cardiac output (CO). There were strong correlations found between the ACE2:ACE and the Ang-(1–7):Ang II ratio highlighting the inter-dependence of the alternate and classical arms of the RAS and thus their potential impact on vascular tone. Conclusions: In human cirrhosis, the alternate RAS is markedly upregulated and the activation of this system is associated strongly with features of the hyperdynamic circulation in advanced human cirrhosis.
Background: The prevalence of metabolic liver diseases is increasing and approved pharmacological treatments are still missing. Many animal models of nonalcoholic fatty liver disease (NAFLD) show a full spectrum of fibrosis, inflammation and steatosis, which does not reflect the human situation since only up to one third of the patients develop fibrosis and nonalcoholic steatohepatitis (NASH). Methods: Seven week old C57Bl/J mice were treated with ethanol, Western diet (WD) or both. The animals’ liver phenotypes were determined through histology, immunohistochemistry, Western blotting, hepatic triglyceride content and gene expression levels. In a human cohort of 80 patients stratified by current alcohol misuse and body mass index, liver histology and gene expression analysis were performed. Results: WD diet and ethanol-treated animals showed severe steatosis, with high hepatic triglyceride content and upregulation of fatty acid synthesis. Mild fibrosis was revealed using Sirius-red stains and gene expression levels of collagen. Inflammation was detected using histology, immunohistochemistry and upregulation of proinflammatory genes. The human cohort of obese drinkers showed similar upregulation in genes related to steatosis, fibrosis and inflammation. Conclusions: We provide a novel murine model for early-stage fatty liver disease suitable for drug testing and investigation of pathophysiology.
Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis
(2020)
Liver cirrhosis represents the common end-stage of chronic liver diseases regardless of its etiology. Patients with compensated disease are mostly asymptomatic, however, progression to a decompensated disease stage is common. The available stratification strategies are often unsuitable to identify patients with a higher risk for disease progression and a limited prognosis. SIBLINGs, soluble glycophosphoproteins, are secreted into the blood by immune-cells. While osteopontin, the most prominent member of the SIBLINGs family, has been repeatedly associated with liver cirrhosis, data on the diagnostic and/or prognostic value of bone sialoprotein (BSP) are scarce and partly inconclusive. In this study, we analyzed the diagnostic and prognostic potential of circulating BSP in comparison to other standard laboratory markers in a large cohort of patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt (TIPS). Serum levels of BSP were similar in patients with different disease stages and were not indicative for prognosis. Interestingly, BSP serum levels did correlate inversely with portal pressure, as well as its surrogates such as platelet count, the portal vein cross-sectional area and correlated positively with the portal venous velocity. In summary, our data highlight that BSP might represent a previously unrecognized marker for portal hypertension in patients with liver cirrhosis.